ArriVent BioPharma, Inc. Common StockAVBPNASDAQ
Loading
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+68.8%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
4.8x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $177.53M | +88.2% |
| 2024 | $94.31M | +26.4% |
| 2023 | $74.59M | +102.1% |
| 2022 | $36.91M | +324.4% |
| 2021 | $8.70M | - |